Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-Operative Erlotinib in Muscle Invasive or Recurrent Urothelial Carcinoma
NCT00749892Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2008
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in urothelial carcinoma (UC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2008; status: completed.
02
Drugs
erlotinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00749892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00749892.